Lineage Cell Therapeutics, Inc. (LCTX)
1.09
+0.01
(+0.93%)
USD |
NYAM |
Sep 08, 16:00
1.10
+0.01
(+0.92%)
After-Hours: 07:30
Lineage Cell Therapeutics PE Ratio
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio Data
| Date | Value |
|---|---|
| September 27, 2019 | 3.601 |
| September 26, 2019 | 3.751 |
| September 25, 2019 | 3.976 |
| September 24, 2019 | 3.826 |
| September 23, 2019 | 3.864 |
| September 20, 2019 | 4.014 |
| September 19, 2019 | 3.938 |
| September 18, 2019 | 3.751 |
| September 17, 2019 | 3.751 |
| September 16, 2019 | 3.788 |
| September 13, 2019 | 3.826 |
| September 12, 2019 | 3.901 |
| September 11, 2019 | 3.901 |
| September 10, 2019 | 3.901 |
| September 09, 2019 | 3.509 |
| September 06, 2019 | 3.454 |
| September 05, 2019 | 3.488 |
| September 04, 2019 | 3.328 |
| September 03, 2019 | 3.376 |
| August 30, 2019 | 3.505 |
| August 29, 2019 | 3.424 |
| August 28, 2019 | 3.338 |
| August 27, 2019 | 3.194 |
| August 26, 2019 | 3.305 |
| August 23, 2019 | 3.723 |
| Date | Value |
|---|---|
| August 22, 2019 | 3.635 |
| August 21, 2019 | 3.600 |
| August 20, 2019 | 3.788 |
| August 19, 2019 | 3.748 |
| August 16, 2019 | 3.864 |
| August 15, 2019 | 3.638 |
| August 14, 2019 | 3.729 |
| August 13, 2019 | 3.826 |
| August 12, 2019 | 3.450 |
| August 09, 2019 | 3.450 |
| August 08, 2019 | 3.713 |
| August 07, 2019 | 3.788 |
| August 06, 2019 | 3.788 |
| August 05, 2019 | 3.672 |
| August 02, 2019 | 3.901 |
| August 01, 2019 | 3.938 |
| July 31, 2019 | 4.126 |
| July 30, 2019 | 4.464 |
| July 29, 2019 | 4.501 |
| July 26, 2019 | 4.651 |
| July 25, 2019 | 4.389 |
| July 24, 2019 | 4.426 |
| July 23, 2019 | 4.201 |
| July 22, 2019 | 4.088 |
| July 19, 2019 | 4.126 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Agenus, Inc. | 2.803 |
| Amgen, Inc. | 24.42 |
| Anika Therapeutics, Inc. | -- |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | -- |
PE Ratio Related Metrics
| PS Ratio | 20.72 |
| PEG Ratio | -6.353 |
| Price to Book Value | 4.526 |
| Price | 1.09 |
| Earnings Yield | -16.91% |
| Market Cap | 275.67M |
| PEGY Ratio | -6.353 |